Clinical potential of necitumumab in non-small cell lung carcinoma

por Genova, Carlo, Hirsch, Fred R
Publicado 2016

Clinical and comparative utility of afatinib in non-small cell lung cancer

por D’Arcangelo, Manolo, Hirsch, Fred R
Publicado 2014

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

por Vergote, Ignace, Macarulla, Teresa, Hirsch, Fred R., Hagemann, Carsten, Miller, David Scott
Publicado 2023

ROS1 Immunohistochemistry Among Major Genotypes of Non—Small-Cell Lung Cancer

por Boyle, Theresa A., Masago, Katsuhiro, Ellison, Kim E., Yatabe, Yasushi, Hirsch, Fred R.
Publicado 2014

sLAG-3 in non-small-cell lung cancer patients’ serum

por He, Yayi, Wang, Yan, Zhao, Sha, Zhao, Chao, Zhou, Caicun, Hirsch, Fred R
Publicado 2018

TIM-3, a promising target for cancer immunotherapy

por He, Yayi, Cao, Jie, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R
Publicado 2018

Treatment of spine metastases in cancer: a review

por Chen, Yu, He, Yayi, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R
Publicado 2019

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status

por Suda, Kenichi, Rozeboom, Leslie, Yu, Hui, Ellison, Kim, Rivard, Christopher J., Mitsudomi, Tetsuya, Hirsch, Fred R.
Publicado 2017

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

por Rodilla, Ananda M., Tavolacci, Sooyun, Cagan, Jazz, Shah, Tanay, Mittan, Sandeep, Mack, Philip C., Hirsch, Fred R.
Publicado 2023

Risk factors for nicotine dependence in Chinese patients with lung cancer

por Gu, Fen, He, Yayi, Mao, Yanjun, Lu, Shiwen, Zhao, Chao, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R
Publicado 2018

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review

por Liu, Yu, Chen, Peixin, Wang, Hao, Wu, Shengyu, Zhao, Sha, He, Yayi, Zhou, Caicun, Hirsch, Fred R.
Publicado 2021

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States

por Veluswamy, Rajwanth, Hirsch, Fred R., Taioli, Emanuela, Wisnivesky, Juan, Strauss, Ross, Harrough, Douglas, Tang, Boxiong, Barnes, Gisoo
Publicado 2022

Radiotherapy and Immunotherapy in Lung Cancer

por Hsieh, Kristin, Dickstein, Daniel R., Runnels, Juliana, Lehrer, Eric J., Rosenzweig, Kenneth, Hirsch, Fred R., Samstein, Robert M.
Publicado 2023

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

por He, Yayi, Rivard, Christopher J., Rozeboom, Leslie, Yu, Hui, Ellison, Kim, Kowalewski, Ashley, Zhou, Caicun, Hirsch, Fred R.
Publicado 2016

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

por He, Yayi, Rozeboom, Leslie, Rivard, Christopher J., Ellison, Kim, Dziadziuszko, Rafał, Yu, Hui, Zhou, Caicun, Hirsch, Fred R.
Publicado 2017

Assessing the association of diabetes with lung cancer risk

por Leiter, Amanda, Charokopos, Antonios, Bailey, Stacyann, Gallagher, Emily J., Hirsch, Fred R., LeRoith, Derek, Wisnivesky, Juan P.
Publicado 2021

Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231...

por San-Millan, Inigo, Martinez, Janel L., Pickard, Shivaun Lueke, Yu, Hui, Hirsch, Fred R., Rivard, Christopher J., Brooks, George A.
Publicado 2023

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases

por He, Yayi, Sun, Wenwen, Wang, Yan, Ren, Shengxiang, Li, Xuefei, Li, Jiayu, Rivard, Christopher J, Zhou, Caicun, Hirsch, Fred R
Publicado 2016

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules

por He, Yayi, Yang, Yang, Kuang, Peng, Ren, Shengxiang, Rozeboom, Leslie, Rivard, Christopher J, Li, Xuefei, Zhou, Caicun, Hirsch, Fred R
Publicado 2017

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2(nd)/3(rd) Line Therapy in Patients with Lung Adenocarcinoma

por He, Yayi, Wang, Yan, Boyle, Theresa, Ren, Shengxiang, Chan, Dan, Rivard, Chris, Li, Xuefei, Li, Jiayu, Zhou, Caicun, Hirsch, Fred R.
Publicado 2016